全球網站
北美洲
歐洲
美國
丹麥
法國
德國
瑞典
瑞士
英國
拉丁美洲
亞太地區
阿根廷
巴西
墨西哥
澳洲
印度
馬來西亞
紐西蘭
泰國
新加坡
瞭解更多關於產品意識的資訊,也就是全球包括製造商、經銷商、消費者對產品反應出的集體意識。
更多資訊
UL Advantage 是一種革新的安全認證方法,提供更快、更具智慧、更靈活的途徑以享受 UL 認證的好處。
更多資訊
幫助符合安全規範的產品進入全球市場。
更多資訊
為不斷成長的可持續性領域提供廣泛的服務。
更多資訊
將 UL 的工程、安全和效能專業知識應用在對大眾福祉相關的關鍵系統上。
更多資訊
提供全球供應鏈所需的產品測試和評估。
更多資訊
提供培訓、顧問服務及領先思維課程,讓企業獲得競爭優勢。
更多資訊
Share

Biocompatibility testing for global regulatory submissions

UL offers the health sciences industries a way to complete another required submission through one provider. UL's biocompatibility test services meet the requirements of the specifications generally accepted by the three major global medical device markets: ISO 10993, USP, or MHLW. Working with UL for biocompatibility testing provides the benefit of test plan consolidation, which can be faster than managing multiple test labs.

Biocompatibility is defined as "compatibility with living tissue or a living system by not being toxic, injurious, or physiologically reactive and not causing immunological rejection." For medical devices, which come into contact with the human body for the purpose of treatment, diagnosis, or physical aid, making sure that every point of contact will not cause irritation, changes in blood composition, or toxic response is especially critical. Even if a material that makes up the medical device has been tested for biocompatibility, processes such as manufacturing, shipping, packaging, and sterilization may have adverse affects on the material's composition and how it reacts in different environments. Because of these potential changes, biocompatibility is an important test protocol that must be completed for every medical device end product prior to receiving global regulatory approvals.

Simultaneous testing

The three global major medical device markets prescribe different test protocols to assess biocompatibility in medical devices. The U.S. FDA and European Union commonly accept the ISO 10993 standards for biocompatibility. USP (U.S. Pharmacopoeia) standards are accepted by the U.S. FDA, are generally regarded as more stringent, and may be used by manufacturers as a marketing tool or for specific uses. Finally, Japan's MHLW has test criteria different from both the ISO 10993 and USP protocols. Through UL's family member, mdt medical device testing, GmbH (MDT), we offer our customers a comprehensive test package to satisfy requirements for global regulatory approvals, and use the "worst case" criteria to minimize testing, samples required, and time.

The UL advantage

  • Custom project planning -- Our staff will work with you to prepare a project plan to meet your current and future product launch needs. This includes meeting with senior-level scientists with years of experience in preparing test protocols to meet regulatory submission requirements.
  • Experience -- Through MDT, a UL company you gain access to over 50 years of experience in analytical chemistry, biocompatibility, toxicology, bioanalytical, microbiological, pharmacology testing, and specialty services.
  • Global accreditation services -- UL is a leader at getting our customers access to existing and emerging markets so you only need to work with one test, regulatory and certification provider to meet your global sales and distribution needs.

Additional resources